PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT 2.1 Preface 2.2 Preface 2.3 Currency conversion rates for US$ PART 03: MARKET LANDSCAPE Market ecosystem Market characteristics Market segmentation analysis PART 04: MARKET SIZING Market definition Market sizing 2018 Market size and forecast 2018-2023 PART 05: FIVE FORCES ANALYSIS Bargaining power of buyers Bargaining power of suppliers Threat of new entrants Threat of substitutes Threat of rivalry Market condition PART 06: PIPELINE PART 07: MARKET SEGMENTATION BY TYPE Market segmentation by type Comparison by type Small molecules - Market size and forecast 2018-2023 Biologics - Market size and forecast 2018-2023 Market opportunity by type PART 08: CUSTOMER LANDSCAPE PART 09: GEOGRAPHIC LANDSCAPE Geographic segmentation Geographic comparison North America - Market size and forecast 2018-2023 Europe - Market size and forecast 2018-2023 Asia - Market size and forecast 2018-2023 ROW - Market size and forecast 2018-2023 Key leading countries Market opportunity PART 10: DECISION FRAMEWORK PART 11: DRIVERS AND CHALLENGES Market drivers Market challenges PART 12: MARKET TRENDS PART 13: VENDOR LANDSCAPE Overview Landscape disruption Competitive scenario PART 14: VENDOR ANALYSIS Vendors covered Vendor classification Market positioning of vendors Bristol-Myers Squibb Co. Eisai Co. Ltd. F. Hoffmann-La Roche Ltd. Merck & Co. Inc. Novartis AG PART 15: APPENDIX Research methodology List of abbreviations Definition of market positioning of vendors PART 16: EXPLORE TECHNAVIO   Exhibit 01: Global oncology therapeutics market Exhibit 02: Segments of global oncology therapeutics market Exhibit 03: Market characteristics Exhibit 04: Market characteristics analysis Exhibit 05: Market segments Exhibit 06: Market definition - Inclusions and exclusions checklist Exhibit 07: Market size 2018 Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions) Exhibit 09: Global market: Year-over-year growth 2019-2023 (%) Exhibit 10: Five forces analysis 2018 Exhibit 11: Five forces analysis 2023 Exhibit 12: Bargaining power of buyers Exhibit 13: Bargaining power of suppliers Exhibit 14: Threat of new entrants Exhibit 15: Threat of substitutes Exhibit 16: Threat of rivalry Exhibit 17: Market condition - Five forces 2018 Exhibit 18: Global brain tumor therapeutics market pipeline: Overview Exhibit 19: Global brain tumor therapeutics market pipeline: Snapshot Exhibit 20: Type - Market share 2018-2023 (%) Exhibit 21: Comparison by type Exhibit 22: Small molecules - Market size and forecast 2018-2023 ($ millions) Exhibit 23: Small molecules - Year-over-year growth 2019-2023 (%) Exhibit 24: Biologics - Market size and forecast 2018-2023 ($ millions) Exhibit 25: Biologics - Year-over-year growth 2019-2023 (%) Exhibit 26: Market opportunity by type Exhibit 27: Customer landscape Exhibit 28: Customer landscape analysis Exhibit 29: Market share by geography 2018-2023 (%) Exhibit 30: Geographic comparison Exhibit 31: North America - Market size and forecast 2018-2023 ($ millions) Exhibit 32: North America - Year-over-year growth 2019-2023 (%) Exhibit 33: Top 3 countries in North America Exhibit 34: Europe - Market size and forecast 2018-2023 ($ millions) Exhibit 35: Europe - Year-over-year growth 2019-2023 (%) Exhibit 36: Top 3 countries in Europe Exhibit 37: Asia - Market size and forecast 2018-2023 ($ millions) Exhibit 38: Asia - Year-over-year growth 2019-2023 (%) Exhibit 39: Top 3 countries in Asia Exhibit 40: ROW - Market size and forecast 2018-2023 ($ millions) Exhibit 41: ROW - Year-over-year growth 2019-2023 (%) Exhibit 42: Top 3 countries in ROW Exhibit 43: Key leading countries Exhibit 44: Market opportunity Exhibit 45: Impact of drivers and challenges Exhibit 46: Vendor landscape Exhibit 47: Landscape disruption Exhibit 48: Vendor landscape analysis Exhibit 49: Vendors covered Exhibit 50: Vendor classification Exhibit 51: Market positioning of vendors Exhibit 52: Bristol-Myers Squibb Co. - Vendor overview Exhibit 53: Bristol-Myers Squibb Co. - Business segments Exhibit 54: Bristol-Myers Squibb Co. - Organizational developments Exhibit 55: Bristol-Myers Squibb Co. - Geographic focus Exhibit 56: Bristol-Myers Squibb Co. - Key offerings Exhibit 57: Bristol-Myers Squibb Co. - Key customers Exhibit 58: Eisai Co. Ltd. - Vendor overview Exhibit 59: Eisai Co. Ltd. - Business segments Exhibit 60: Eisai Co. Ltd. - Organizational developments Exhibit 61: Eisai Co. Ltd. - Geographic focus Exhibit 62: Eisai Co. Ltd. - Segment focus Exhibit 63: Eisai Co. Ltd. - Key offerings Exhibit 64: Eisai Co. Ltd. - Key customers Exhibit 65: F. Hoffmann-La Roche Ltd. - Vendor overview Exhibit 66: F. Hoffmann-La Roche Ltd. - Business segments Exhibit 67: F. Hoffmann-La Roche Ltd. - Organizational developments Exhibit 68: F. Hoffmann-La Roche Ltd. - Geographic focus Exhibit 69: F. Hoffmann-La Roche Ltd. - Segment focus Exhibit 70: F. Hoffmann-La Roche Ltd. - Key offerings Exhibit 71: F. Hoffmann-La Roche Ltd. - Key customers Exhibit 72: Merck & Co. Inc. - Vendor overview Exhibit 73: Merck & Co. Inc. - Business segments Exhibit 74: Merck & Co. Inc. - Organizational developments Exhibit 75: Merck & Co. Inc. - Geographic focus Exhibit 76: Merck & Co. Inc. - Segment focus Exhibit 77: Merck & Co. Inc. - Key offerings Exhibit 78: Merck & Co. Inc. - Key customers Exhibit 79: Novartis AG - Vendor overview Exhibit 80: Novartis AG - Business segments Exhibit 81: Novartis AG - Organizational developments Exhibit 82: Novartis AG - Geographic focus Exhibit 83: Novartis AG - Segment focus Exhibit 84: Novartis AG - Key offerings Exhibit 85: Novartis AG - Key customers Exhibit 86: Validation techniques employed for market sizing Exhibit 87: Definition of market positioning of vendors

Bristol-Myers Squibb Co. Eisai Co. Ltd. F. Hoffmann-La Roche Ltd. Merck & Co. Inc. Novartis AG